Kidney transplant study: which drug better prevents rejection?

NCT ID NCT02377193

Completed Disease control Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two different drug combinations (Simulect or ATG, plus standard medications) in 60 kidney transplant patients at high risk of rejection. The goal was to see which approach better prevents treatment failure, including rejection, graft loss, or death, within 6 months. Results could help tailor therapy for sensitized patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Simulect (basiliximab) and ATG Fresenius (anti-thymocyte globulin)
What this could lead to: If successful, this could help doctors choose the safer and more effective induction therapy for sensitized kidney transplant patients, reducing rejection risk.
What could go wrong: This is a small pilot study with only 60 participants, so results may not apply to all patients. Both drugs have side effects, including infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute transplant rejection end stage renal failure transplant rejection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL TRANSPLANT REJECTION

Contacts and locations

Locations

UHToulouse

Toulouse, France, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.